【导读】针对肿瘤特异性新抗原的免疫治疗具有潜力，但它们在肿瘤细胞上的超低表达，对T细胞治疗提出了挑战。在这项研究中，团队发现，嵌合抗原受体（CARs）在针对人类白细胞抗原（HLA）I类呈现的p53R175H新抗原时，其敏感性比T细胞受体（TCRs）低 ...

The University of Cambridge said the Trinity Cambridge Research Studentships (TCRS) have been created to respond to declining ...

Trinity College and the University of Cambridge will provide £48 million over 5 years to fund around 30 PhD students ...

2024年10月16日，专注于肿瘤和自免疾病通用型γδT细胞疗法的上市公司Adicet ...

T cells use T cell receptors (TCRs) to identify and eliminate diseased cells. T cells equipped with cancer-targeting TCRs can detect and eliminate cancer cells, and TCR-based T cell therapies have ...

The presentation ”Seamless Integration of a Universal Epitope into Recombinant TCRs for Tagging and Tracking of TCR-T Cells Expressing 3S TCRs” and the poster “UniTope & TraCR – A universal tagging ...

Nobel laureate Dr Venki Ramakrishnan supports a new £48 million programme by Trinity College and the University of Cambridge to offer fully funded PhDs. The initiative aims to attract top talent ...

Besides demonstrating that there is no intrinsic structural block to generating high-affinity TCRs, the findings could have implications for a variety of clinical applications. The approach ...

在动荡的市场环境中，TCRT股票已触及52周低点，交易价格为2.06美元。这一价格水平反映了生物技术板块面临的巨大压力，因为投资者正在重新评估他们对整个行业面临的不利因素的预期。过去一年，该股票的表现受到显著影响，TCRT背后的公司ZIOPHARM Oncology经历了惊人的83.93%的一年跌幅。这种急剧下跌凸显了该公司在竞争激烈且快速发展的市场中所面临的波动和挑战。

"Among other factors, the success of TCR-guided therapies for solid tumors hinges on several key innovations: developing optimal TCRs that are safe, sensitive, and specific; enhancing engineered cells ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...